INT195414

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.72
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 65
Total Number 68
Disease Relevance 31.22
Pain Relevance 15.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nuclear envelope (ALOX5AP) endoplasmic reticulum (ALOX5AP) nucleus (ALOX5AP)
enzyme binding (ALOX5AP)
Anatomy Link Frequency
osteoblasts 18
chondrocytes 3
muscle 2
neutrophils 2
plasma 1
ALOX5AP (Homo sapiens)
Pain Link Frequency Relevance Heat
Osteoarthritis 4467 99.84 Very High Very High Very High
COX-2 inhibitor 141 97.96 Very High Very High Very High
antagonist 14 97.52 Very High Very High Very High
Inflammation 576 96.00 Very High Very High Very High
cINOD 316 91.60 High High
Pain 95 75.76 Quite High
Inflammatory response 75 72.12 Quite High
licofelone 54 70.40 Quite High
Inflammatory mediators 21 62.00 Quite High
Arthritis 36 54.80 Quite High
Disease Link Frequency Relevance Heat
Osteoarthritis 4574 99.84 Very High Very High Very High
Atherosclerotic Plaque 8 99.08 Very High Very High Very High
Stress 24 96.44 Very High Very High Very High
INFLAMMATION 773 96.00 Very High Very High Very High
Calcification 48 94.04 High High
Atherosclerosis 178 88.60 High High
Osteophyte 88 88.16 High High
Anaphylactic Hypersensitivity 1 86.56 High High
Hypersensitivity 73 85.76 High High
Myocardial Infarction 16 82.24 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Their observed decrease (and negative correlation with the ALOX5AP expression) following simvastatin treatment may thus be functionally linked to increased oxidative stress and inflammation in muscle.
Gene_expression (expression) of ALOX5AP in muscle associated with stress and inflammation
1) Confidence 0.72 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762369 Disease Relevance 0.32 Pain Relevance 0.07
As revealed by results listed in Table 2, the lowest limit for FLAP length lies in a narrow (four amino acids) range of ?
Gene_expression (length) of FLAP
2) Confidence 0.66 Published 2006 Journal Nucleic Acids Research Section Body Doc Link PMC1540723 Disease Relevance 0.06 Pain Relevance 0
Parameter evaluation and the resulting FLAP set
Gene_expression (set) of FLAP
3) Confidence 0.66 Published 2006 Journal Nucleic Acids Research Section Body Doc Link PMC1540723 Disease Relevance 0 Pain Relevance 0
Non-allergen dataset for FLAP extraction
Gene_expression (extraction) of FLAP
4) Confidence 0.66 Published 2006 Journal Nucleic Acids Research Section Body Doc Link PMC1540723 Disease Relevance 0 Pain Relevance 0
The significance of this observation remains to be elucidated but it is interesting that a link between the Leukotriene B4 (a lipid synthesised via ALOX5AP) and the release of arachidonate from phosphatidylethanolamine in human neutrophils has been established [30].
Gene_expression (synthesised) of ALOX5AP in neutrophils
5) Confidence 0.62 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762369 Disease Relevance 0.24 Pain Relevance 0.05
Our analyses identified ALOX5AP gene expression in muscle had a high positive regression coefficients with plasma levels of phosphatidylethanolamine (42?
Gene_expression (expression) of ALOX5AP gene in plasma
6) Confidence 0.62 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762369 Disease Relevance 0.16 Pain Relevance 0.04
The following 5 genes were significantly upregulated: ALOX5AP (+3.6-fold, p?
Gene_expression (+3.6) of ALOX5AP
7) Confidence 0.62 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762369 Disease Relevance 0.07 Pain Relevance 0.07
The following 5 genes were significantly upregulated: ALOX5AP (+3.6-fold, p?
Gene_expression (fold) of ALOX5AP
8) Confidence 0.62 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762369 Disease Relevance 0.07 Pain Relevance 0.07
We also found that the plasma lipidomic changes following simvastatin treatment correlate with the muscle expression of the arachidonate 5-lipoxygenase-activating protein.


Gene_expression (expression) of arachidonate 5-lipoxygenase-activating protein in muscle
9) Confidence 0.58 Published 2006 Journal PLoS ONE Section Abstract Doc Link PMC1762369 Disease Relevance 0.14 Pain Relevance 0.04
LTB4 has been detected in human carotid artery, atherosclerotic plaques and is derived from the 5-LO metabolism (via ALOX5AP and through G-coupled protein receptors) of arachidonic acid [21, 44].
Gene_expression (through) of ALOX5AP in plaques associated with atherosclerotic plaque
10) Confidence 0.58 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2878676 Disease Relevance 0.84 Pain Relevance 0.06
of the gene), one in ALOX5 (rs2115819, P = .090, intron 3), and two in ALOX5AP (rs9506352, P = .097, intron 2; rs4769060, P = .073, intron 4).
Gene_expression (two) of ALOX5AP
11) Confidence 0.58 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2878676 Disease Relevance 0.11 Pain Relevance 0
Four lipoxygenase pathway variants contributed to variation in CorCP—one in ALOX5 (rs2115819), one in ALOX12 (rs2271316), and two in ALOX5AP (rs9506352 and rs4769060).
Gene_expression (two) of ALOX5AP
12) Confidence 0.58 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2878676 Disease Relevance 0.42 Pain Relevance 0
For CarCP, the ALOX5AP rs10507391 SNP exhibited an additive pattern.
Gene_expression (rs10507391) of ALOX5AP
13) Confidence 0.58 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2878676 Disease Relevance 0.11 Pain Relevance 0
Our real-time RT-PCR results demonstrated that HNE induced FLAP expression after 24 hours of treatment (210% of control, P < 0.001) and the level was even higher after 72 hours (315% of control, P < 0.001) (Figure 6a, b).
Gene_expression (expression) of FLAP
14) Confidence 0.55 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875653 Disease Relevance 0.14 Pain Relevance 0.07
Using the nonspecific inhibitor of COX, naproxen, we abolished HNE-induced FLAP expression in OA chondrocytes after short or long periods of incubation.
Gene_expression (expression) of FLAP in chondrocytes associated with osteoarthritis
15) Confidence 0.55 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875653 Disease Relevance 0.28 Pain Relevance 0.14
Several investigations have shown that 5-LOX and FLAP expression is regulated by PGE2 [28,42].
Gene_expression (expression) of FLAP
16) Confidence 0.55 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875653 Disease Relevance 0.08 Pain Relevance 0.04
FLAP mRNA expression occurred earlier, after 8 hours of incubation, compared with 5-LOX (48 hours).
Gene_expression (expression) of FLAP mRNA
17) Confidence 0.55 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875653 Disease Relevance 0.42 Pain Relevance 0.21
HNE-induced changes in 5-LOX and FLAP mRNA expression were evaluated as a percentage of control (untreated cells).
Gene_expression (expression) of FLAP mRNA
18) Confidence 0.55 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875653 Disease Relevance 0 Pain Relevance 0
PGE2 inhibition regulates 5-LOX and FLAP expression differentially.
Gene_expression (expression) of FLAP
19) Confidence 0.55 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875653 Disease Relevance 0.20 Pain Relevance 0.10
HNE-induced changes in 5-LOX and FLAP mRNA expression were evaluated as a percentage of control.
Gene_expression (expression) of FLAP mRNA
20) Confidence 0.55 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875653 Disease Relevance 0.15 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox